Women with HIV (WHIV) on ART face an increased risk of cardiovascular disease (CVD), including heart failure. Aortic vascular dysfunction, reflected by increased aortic pulse wave velocity (aPWV), presages, predicts, and promotes adverse CVD outcomes. Moreover, aortic vascular dysfunction – a proxy for vascular aging – is highly influenced by the local inflammatory milieu. Comparisons of aortic vascular function among predominantly male cohorts with vs. without HIV have yielded conflicting results. Cognizant of sex-specific patterns of HIV-associated immune dysregulation, we compared aPWV among asymptomatic ART-treated women with vs. without HIV. We hypothesized that WHIV would evidence vascular dysfunction in association with monocyte activation.
20 WHIV and 14 matched women without HIV underwent cardiac MRI, as well as metabolic and immune phenotyping. Women with a history of CVD, diabetes, or significant kidney disease were excluded.
Women with vs. without HIV had comparable age (52 vs. 53 years) and BMI (32 vs. 32 kg/m2). WHIV exhibited heightened systemic monocyte activation, reflected by increased levels of sCD163 (1260 vs 938 ng/mL, P=0.005). Among WHIV, duration of HIV was 19±8 years, CD4 count was 773 (526,1202) cells/mm3 and viral load was 19 (19,19) copies/mL. aPWV was higher among women with vs. without HIV (8.6±1.3 vs 6.5±1.3 m/s), P<0.0001; Fig. 1A). Among the whole group and each sub-group, aPWV did not relate to age, BMI, cigarette smoking burden, or SBP. Among the whole group and among WHIV, aPWV related to sCD163 levels (whole group: R=0.65, P<0.0001; WHIV: R=0.73, P=0.0003; Fig. 1B). Among the whole group and among WHIV, aPWV also related to extracellular volume – a measure of myocardial fibrosis (whole group: R=0.54, P=0.001; WHIV: R=0.47, P=0.04). Both HIV status and sCD163 levels independently predicted aPWV, even after controlling for age, BMI, cigarette smoking status, and SBP (R2=0.63, P=0.0002; HIV status: P=0.02; sCD163: P=0.01). Among WHIV, sCD163 levels independently predicted aPWV after controlling for duration of HIV, CD4 count, and HIV viral load (R2=0.62, P=0.007; sCD163: P=0.0005).
Asymptomatic ART-treated WHIV demonstrated increased aPWV. Among WHIV, aPWV related to heightened monocyte activation as well as to downstream CVD pathology. Additional studies are needed to identify targeted immune-modulatory therapies which slow the progression from vascular dysfunction to incident CVD in this at-risk population.